Cargando…

Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty

We sought to determine whether the myopic progression of patients with central precocious puberty (CPP) who were undergoing treatment differed from that of their healthy peers with normal pubertal onset and progression. Eighteen girls with CPP and 14 age-matched controls who underwent regular ophtha...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Seung Ah, Lee, Hae Sang, Kim, Seung Woo, Hwang, Jin Soon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995965/
https://www.ncbi.nlm.nih.gov/pubmed/33668206
http://dx.doi.org/10.3390/children8030171
_version_ 1783670017644036096
author Chung, Seung Ah
Lee, Hae Sang
Kim, Seung Woo
Hwang, Jin Soon
author_facet Chung, Seung Ah
Lee, Hae Sang
Kim, Seung Woo
Hwang, Jin Soon
author_sort Chung, Seung Ah
collection PubMed
description We sought to determine whether the myopic progression of patients with central precocious puberty (CPP) who were undergoing treatment differed from that of their healthy peers with normal pubertal onset and progression. Eighteen girls with CPP and 14 age-matched controls who underwent regular ophthalmic examinations for at least 1 year were included. All the CPP patients received a 3.75 mg leuprolide acetate depot subcutaneously every 28 days. The spherical equivalent (SE) and axial length (AL) for myopia progression and the pubertal parameters (height, body weight, body mass index, Tanner stage, and bone age) were compared between the two groups. Of 32 subjects with a mean age of 8.6 ± 0.7 years, the SEs and ALs did not differ at baseline between the two groups, which had similar weight and similar body mass index. After 1 year, both the CPP patients and controls showed myopic progression, with an average myopic shift of −0.73 ± 0.48 diopters (D) and AL elongation with a mean change of 0.44 ± 0.61 mm. The SE and AL changes over 1 year were greater in the controls than those in the CPP patients, which was not statistically significant (–0.85 ± 0.55 D vs. –0.64 ± 0.41 D and 0.55 ± 0.89 mm vs. 0.35 ± 0.22 mm, respectively). The change in AL correlated significantly with the change in the height (β = 0.691, p = 0.039). In this 1-year study, the CPP patients with treatments trended to show less myopic progression than the controls.
format Online
Article
Text
id pubmed-7995965
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79959652021-03-27 Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty Chung, Seung Ah Lee, Hae Sang Kim, Seung Woo Hwang, Jin Soon Children (Basel) Article We sought to determine whether the myopic progression of patients with central precocious puberty (CPP) who were undergoing treatment differed from that of their healthy peers with normal pubertal onset and progression. Eighteen girls with CPP and 14 age-matched controls who underwent regular ophthalmic examinations for at least 1 year were included. All the CPP patients received a 3.75 mg leuprolide acetate depot subcutaneously every 28 days. The spherical equivalent (SE) and axial length (AL) for myopia progression and the pubertal parameters (height, body weight, body mass index, Tanner stage, and bone age) were compared between the two groups. Of 32 subjects with a mean age of 8.6 ± 0.7 years, the SEs and ALs did not differ at baseline between the two groups, which had similar weight and similar body mass index. After 1 year, both the CPP patients and controls showed myopic progression, with an average myopic shift of −0.73 ± 0.48 diopters (D) and AL elongation with a mean change of 0.44 ± 0.61 mm. The SE and AL changes over 1 year were greater in the controls than those in the CPP patients, which was not statistically significant (–0.85 ± 0.55 D vs. –0.64 ± 0.41 D and 0.55 ± 0.89 mm vs. 0.35 ± 0.22 mm, respectively). The change in AL correlated significantly with the change in the height (β = 0.691, p = 0.039). In this 1-year study, the CPP patients with treatments trended to show less myopic progression than the controls. MDPI 2021-02-24 /pmc/articles/PMC7995965/ /pubmed/33668206 http://dx.doi.org/10.3390/children8030171 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Chung, Seung Ah
Lee, Hae Sang
Kim, Seung Woo
Hwang, Jin Soon
Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
title Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
title_full Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
title_fullStr Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
title_full_unstemmed Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
title_short Myopic Progression in Girls with Gonadotrophin-Releasing Hormone Agonist Treatment for Central Precocious Puberty
title_sort myopic progression in girls with gonadotrophin-releasing hormone agonist treatment for central precocious puberty
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995965/
https://www.ncbi.nlm.nih.gov/pubmed/33668206
http://dx.doi.org/10.3390/children8030171
work_keys_str_mv AT chungseungah myopicprogressioningirlswithgonadotrophinreleasinghormoneagonisttreatmentforcentralprecociouspuberty
AT leehaesang myopicprogressioningirlswithgonadotrophinreleasinghormoneagonisttreatmentforcentralprecociouspuberty
AT kimseungwoo myopicprogressioningirlswithgonadotrophinreleasinghormoneagonisttreatmentforcentralprecociouspuberty
AT hwangjinsoon myopicprogressioningirlswithgonadotrophinreleasinghormoneagonisttreatmentforcentralprecociouspuberty